The use of ophthalmic serum is a critical component in the management of corneal ulcerative disease in veterinary ophthalmology. Corneal ulcers can progress rapidly if not managed aggressively. After a corneal injury, enzymes can be released by both bacteria (if present) and white blood cells. These enzymes, such as matrix metalloproteinases (MMPs) and serine proteinases, can lead to corneal breakdown or even corneal melting (keratomalacia). This can lead to a progressively deeper ulceration. Severe vision and globe threatening complications can occur, such has corneal perforation.

Mechanism of serum in treating ulcerative keratitis.

Ophthalmic serum plays a pivotal role in halting the corneal degradation process by providing anti-collagenase and anti-protease activity. The presence of alpha-2 macroglobulin, a broad-spectrum proteinase inhibitor, as well as specific MMP inhibitors, makes serum particularly effective in reducing the enzymatic breakdown of the corneal matrix. By inhibiting these enzymes, serum slows or prevents further collagen degradation, thus stabilizing the corneal stroma and preventing perforation.

In addition to its anti-collagenase properties, serum has a rich content of growth factors and nutrients for the surface of the eye, including epidermal growth factor, fibronectin, alpha-2-macroglobulin, and platelet-derived growth factors. These factors aid in appropriate corneal healing, reducing the risk of long-term scarring and visual impairment.

Advantages of serum as an anti-collagenase agent.

Serum is favored in veterinary ophthalmology due to its several key advantages over synthetic or non-biologic alternatives:

Clinical application and benefits.

Ophthalmic serum is most commonly employed in cases of deep corneal ulcers or keratomalacia where the risk of perforation is high. It is typically used in conjunction with other therapeutic agents such as topical antibiotics and lubricants to provide a multi-modal approach to treatment. In this context, serum’s anti-collagenase activity complements antibiotic therapy by addressing the enzymatic damage caused by infection, while its growth factors promote tissue repair and regeneration.

Moreover, the use of serum in these cases can lead to reduced corneal scarring, a common complication in healing ulcers, which is particularly important for preserving vision. The biologically active components of serum not only aid in stabilizing the corneal structure but also facilitate smoother, more organized epithelial healing.

Conclusion.

Ophthalmic serum has become a cornerstone in the treatment of corneal ulcerative disease within veterinary medicine. Its anti-collagenase and anti-proteinase properties, combined with growth factors and nutrients, make it an invaluable tool in the ophthalmologist’s therapeutic arsenal. Given its safety, accessibility, and broad-spectrum efficacy, serum continues to be the preferred anti-collagenase agent for managing complex corneal ulcers in veterinary practice.